Thank you for Subscribing to Life Science Review Weekly Brief
SomaLogic and Illumina have teamed up to provide customers in the research, clinical, and application markets, unique capabilities from both companies.
Fremont, CA: “This is truly a transformational partnership that will democratize and accelerate our understanding of the human proteome,” comments SomaLogic Chief Executive Officer Roy Smythe, M.D. “It definitively signals that the era of proteomics is here and that SomaLogic, and now Illumina, will lead that era.” SomaLogic, a leader in data-driven proteomics technology, has launched a global strategic partnership with Illumina, the world's leading provider of next-generation sequencing technology. The multi-year deal will bring genomics and proteomics technology platforms together in a major commercial alliance to better enable and empower proteomics and multi-omics research around the world.
The firms will collaborate to produce co-exclusive, co-branded proteomics solutions based on next-generation sequencing (NGS). The two companies will combine Illumina's global commercial infrastructure with SomaLogic's unique proteomics platform, which includes proprietary synthetic aptamer reagents
capable of measuring and identifying 7,000 human proteins, unique bioinformatics tools and capabilities, and the world's largest clinical proteomics database.
For customers in the research, clinical, and applied areas, the cooperation brings together unique strengths from each business. Illumina is a leader in DNA sequencing and array-based technologies around the world. SomaLogic has a 20-year track record of providing highly repeatable measurements of circulating proteins using slow off-rate modified aptamers, known as SOMAmer® reagents, and its patented SomaScan® Platform.
Illumina will develop and implement NGS-based protein identification and measurement tools into laboratories throughout the world, as well as enable the development and usage of high-plex protein pattern recognition tests as part of the deal. SomaLogic was the first to use this method of diagnosis, starting its SomaSignal test program in 2019. The company now offers 12 protein pattern recognition tests created in the lab for a variety of human illnesses and disorders.